ARTICLE | Finance

Knopp Gives Back

Biogen Idec deal in ALS allows Knopp Neurosciences to issue dividend to investors

August 30, 2010 7:00 AM UTC

After licensing its only clinical candidate to Biogen Idec Inc. (NASDAQ:BIIB), Knopp Neurosciences Inc. decided it could afford to give a dividend to investors.

Knopp granted Biogen Idec an exclusive, worldwide license to develop and commercialize dexpramipexole (KNS-760704).The small modulator of mitochondrial bioenergetics with an unknown target, is expected to enter Phase III testing for amyotrophic lateral sclerosis (ALS) in 1H11. The compound is an optical enantiomer of pramipexole, a dopamine agonist...